Aredia, pamidronate disodium (APD), is a bone-resorption inhibitor available in 30-mg or 90-mg vials for intravenous administration.
Aredia is indicated for the following:
HYPERCALCEMIA OF MALIGNANCY
Aredia, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with Aredia. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of Aredia in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established.
Aredia is indicated for the treatment of patients with moderate to severe Paget's disease of bone. The effectiveness of Aredia was demonstrated primarily in patients with serum alkaline phosphatase >/=3 times the upper limit of normal. Aredia therapy in patients with Paget's disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by >/=50% in at least 50% of patients, and by >/=30% in at least 80% of patients. Aredia therapy has also been effective in reducing these biochemical markers in patients with Paget's disease who failed to respond, or no longer responded to other treatments.
OSTEOLYTIC BONE METASTASES OF BREAST CANCER AND OSTEOLYTIC LESIONS OF MULTIPLE MYELOMA
Aredia is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The Aredia treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated (see CLINICAL PHARMACOLOGY, Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma, Clinical Trials section).
Published Studies Related to Aredia (Pamidronate)
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. [2011.05]
A prospective, multicenter, randomized trial comparing pamidronate administration (60-90 mg once a month for 1 year) versus simple observation in 177 patients with asymptomatic myeloma was performed to explore whether the administration of this drug reduces the rate of and/or the time to progression to overt, symptomatic disease...
Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant. [2011.01]
This study evaluates the efficacy of low doses of pamidronate after renal transplantation to prevent bone loss in osteopenic patients. Results show that pamidronate is safe and significantly reduced spinal bone loss when administered immediately after renal transplantation. INTRODUCTION: The purpose of this work is to evaluate the efficacy of two intravenous infusions of pamidronate in the immediate post-transplant period in a renal transplant (RT) population... CONCLUSION: A low dose of pamidronate prevents bone loss in osteopenic patients when administered immediately after RT.
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. [2010.10]
BACKGROUND: Compared with placebo, prophylactic treatment with bisphosphonates reduces risk of skeletal events in patients with multiple myeloma. However, because of toxicity associated with long-term bisphosphonate treatment, establishing the lowest effective dose is important. This study compared the effect of two doses of pamidronate on health-related quality of life and skeletal morbidity in patients with newly diagnosed multiple myeloma... INTERPRETATION: Monthly infusion of pamidronate 30 mg should be the recommended dose for prevention of bone disease in patients with multiple myeloma. FUNDING: Nordic Cancer Union and Novartis Healthcare. Copyright (c) 2010 Elsevier Ltd. All rights reserved.
Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. [2009.05]
BACKGROUND: Kidney transplantation is associated with an increased risk of bone fracture and rapid loss of bone mineral density after kidney transplantation... CONCLUSION: Pamidronate protects against posttransplantation bone loss at the lumbar spine and Ward's area of the hip.
Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. [2009.02]
Rapid bone loss and high rates of fractures occur following liver transplantation... However, pamidronate does not reduce bone loss at the femoral neck and furthermore it does not reduce skeletal fractures.
Clinical Trials Related to Aredia (Pamidronate)
Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma [Completed]
Drugs used in chemotherapy, such as arsenic trioxide and pamidronate, work in different ways
to stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Arsenic trioxide and pamidronate may also stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth. Pamidronate may also stop the growth of
cancer cells by blocking blood flow to the cancer. Giving arsenic trioxide together with
pamidronate may kill more cancer cells. This phase I trial is studying the side effects and
best dose of arsenic trioxide and pamidronate in treating patients with advanced solid
tumors or multiple myeloma
Efficacy of Pamidronate in the Treatment of Bone Loss Associated With Liver Transplant [Completed]
The aims of this study are to prospectively evaluate the efficacy of two intravenous
infusions of pamidronate 90 mg, associated with calcium and calcidiol, in the early
post-transplant period, on bone loss in liver transplant recipients, and to asses the safety
of this treatment.
Study of Pamidronate for the Prevention of Heterotopic Ossification [Withdrawn]
The purpose of this study is to determine whether Bisphosphonates in comparison to radiation
therapy are effective in the prophylaxis and treatment of heterotopic ossification in high
The Use of Bisphosphonates in the Treatment of Avascular Necrosis of the Femoral Head [Completed]
To determine the safety and effectiveness of pamidronate in patients with radiographically
proven avascular necrosis which are the result of unstable (acute) slipped capital femoral
epiphysis, traumatic proximal femur fractures, traumatic hip dislocations, or idiopathic in
Pamidronate to Treat Osteogenesis Imperfecta in Children [Completed]
This study will evaluate the effect of pamidronate a drug that decreases bone resorption
(breakdown) on osteogenesis imperfecta. This is a genetic disorder of collagen, the major
protein in bone. The abnormal collagen causes weak bones, and children with severe
osteogenesis imperfecta sustain many fractures throughout their lives. They also have
growth deficiency, curvature of the spine, crumbling teeth, hearing loss, easy bruising and
heart and lung problems. The study will compare bone density, quality and strength, final
adult height, trunk height, and functional ability in children who receive 1) pamidronate
every 3 months, 2) pamidronate every 3 months + growth hormone injections, 3) pamidronate
every 6 months, or 4) pamidronate every 6 months + growth hormone injections.
Children 2 years of age and older with severe osteogenesis imperfecta (types III and IV) may
be eligible for this study. Those enrolled will be randomly assigned to groups according to
age; children two to four years of age will be randomly assigned to receive pamidronate
every 3 or every 6 months. Children four years of age and older may participate in the
growth hormone treatment groups. These children will continue on growth hormone until they
reach their adult height or fail to grow as much as would be expected for someone on growth
Patients will be followed in the clinic every 3 months for a history, physical examination,
X-rays, blood tests, and measurements (weight, head circumference, and bone lengths).
Children will receive a 3 to 4 hour infusion of pamidronate through an intravenous catheter
(thin flexible tube placed in a vein) once a day for 3 days each visit. (Once inserted, the
catheter is left in place to avoid multiple needle sticks for administering the drug and
collecting blood samples.) Children who are taking growth hormone will be given the drug at
the first treatment visit. At that time, the accompanying parent will be instructed on how
to mix the drug and give injections. The child receives an injection 6 days a week (Sunday
Reports of Suspected Aredia (Pamidronate) Side Effects
Osteonecrosis of JAW (1350),
Back Pain (701),
Spinal Osteoarthritis (575), more >>
Page last updated: 2011-12-09